Development of individual therapy for overcoming HGF-induced molecular targeted drug-resistance in EGFR-mutant lung cancer

• Project/Area Number: 21390256
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Kanazawa University
• Principal Investigator: YANO Seiji 金沢大学, がん進展制御研究所, 教授 (30294672)
• Co-Investigator(Kenkyū-buntansha): WANG Wei 金沢大学, がん研究所, 博士研究員 (80467117) ; YAMADA Tadaaki 金沢大学, 附属病院, 助教 (00507048) ; TAKEUCHI Shinji 金沢大学, がん進展制御研究所, 助教 (90565384)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000); Fiscal Year 2011: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2010: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000); Fiscal Year 2009: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
• Keywords: 肺癌 / EGFR-TKI / 薬剤耐性 / HGF / Met / EGFR遺伝子変異 / バイオマーカー / PI3K / 公子標的治療 / 肝細胞増殖因子 / MET / 線維芽細胞 / 上皮成長因子受容体 / ゲフィチニブ

Research Abstract

The purpose of this study was to develop novel therapy for overcoming HGF-induced EGFR-TKI resistance and establish biomarkers which predict the HGF-induced resistance in lung cancer. We found that inhibitors of HGF-Met could overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer cells in vitro and in vivo. Our study with clinical specimens reveled that high levels of HGF were detected in tumors with acquired and intrinsic resistance to EGFR-TKI and was the most prevalent factor for resistance, at least in Japanese patients with EGFR-mutant lung cancer. We further demonstrated that levels of HGF in plasma before EGFR-TKI treatment inversely correlated with clinical response in lung cancer. These finding suggest that HGF is the important target and biomarker of individual therapy with EGFR-TKI in lung cancer.

Research Products

• [Journal Article] Ligand-triggered resistance to molecular targeted drugs in lung cancer : roles of HGF and EGFR ligands (2012)
  • Author(s): Yano S, Takeuchi S, Nakagawa T, Yamada T
  • Journal Title: Cancer Sci Volume: (In press) Issue: 7 Pages: 1189-1194
  • DOI: 10.1111/j.1349-7006.2012.02279.x
  • Peer Reviewed
• [Journal Article] E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells (2012)
  • Author(s): Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Uenaka T, Yano S
  • Journal Title: Clin Cancer Res Volume: 18 Issue: 6 Pages: 1663-71
  • DOI: 10.1158/1078-0432.ccr-11-1171
  • Peer Reviewed
• [Journal Article] Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis (2012)
  • Author(s): Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S.
  • Journal Title: J Thorac Oncol Volume: (in press)
  • NAID: 40019570662
  • Peer Reviewed
• [Journal Article] T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI (2012)
  • Author(s): Uramoto T, Yano S, Tanaka F
  • Journal Title: Lung Cancer Volume: 76 Issue: 1 Pages: 129-30
  • DOI: 10.1016/j.lungcan.2012.01.010
  • Peer Reviewed
• [Journal Article] Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer (2012)
  • Author(s): Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S
  • Journal Title: J Thorac Oncol Volume: 7 Issue: 2 Pages: 272-80
  • DOI: 10.1097/jto.0b013e3182398e69
  • Peer Reviewed
• [Journal Article] Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis (2012)
  • Author(s): Koizumi H, Yano S, et al.
  • Journal Title: J Thorac Oncol Volume: (In press)
  • Peer Reviewed
• [Journal Article] Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort (2011)
  • Author(s): Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto U, Yasumoto Y, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M.
  • Journal Title: J Thorac Oncol Volume: 6 Issue: 12 Pages: 2011-7
  • DOI: 10.1097/jto.0b013e31823ab0dd
  • Peer Reviewed
• [Journal Article] Reaction of plasma hepatocyte growth factor level in lung cancer patients treated with EGFR-TKIs (2011)
  • Author(s): Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K.
  • Journal Title: Int J Cancer Volume: 126 Issue: 6 Pages: 1410-6
  • DOI: 10.1002/ijc.25799
  • Peer Reviewed
• [Journal Article] Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer (2011)
  • Author(s): Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S
  • Journal Title: Clin Cancer Res Volume: 17 Issue: 8 Pages: 2260-9
  • DOI: 10.1158/1078-0432.ccr-10-1993
  • Peer Reviewed
• [Journal Article] The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer (2011)
  • Author(s): Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Takeuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S.
  • Journal Title: Clin Cancer Res Volume: 17 Issue: 11 Pages: 3619-30
  • DOI: 10.1158/1078-0432.ccr-10-2475
  • Peer Reviewed
• [Journal Article] E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor (2011)
  • Author(s): Ogino H, Hanibuchi M, Kakiuchi S, Trung Van The, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.
  • Journal Title: Mol Cancer Ther Volume: 10 Issue: 7 Pages: 1218-28
  • DOI: 10.1158/1535-7163.mct-10-0707
  • Peer Reviewed
• [Journal Article] Pleural mesothelioma instigates tumor associated fibroblasts to promote prog-ression via malignant cytokine network (2011)
  • Author(s): Li Q, Wang W, Yamada T, Matsumoto K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yano S.
  • Journal Title: Am J Pathol Volume: 179 Issue: 3 Pages: 1483-93
  • DOI: 10.1016/j.ajpath.2011.05.060
  • Peer Reviewed
• [Journal Article] Genetically engineered humanized anti-ganglioside GM2 anti-body against multiple organ metastasis produced by GM2 expressing small cell lung cancer (2011)
  • Author(s): Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S.
  • Journal Title: Cancer Sci Volume: 102 Issue: 12 Pages: 2157-63
  • DOI: 10.1111/j.1349-7006.2011.02093.x
  • Peer Reviewed
• [Journal Article] Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts (2011)
  • Author(s): Shiirevnyamba A, Yano S, et al.
  • Journal Title: Br J Cancer Volume: 104 Issue: 3 Pages: 505-513
  • DOI: 10.1038/sj.bjc.6606070
  • Peer Reviewed
• [Journal Article] A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer (2011)
  • Author(s): Tomimoto H, Yano S, et al.
  • Journal Title: Oncology Letter Volume: 2 Pages: 465-470
  • Peer Reviewed
• [Journal Article] Transient P13K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. (2011)
  • Author(s): Donev IS, Yano S, et al.
  • Journal Title: Clin Cancer Res Volume: 17(In press) Pages: 2260-2269
  • Peer Reviewed
• [Journal Article] Epithelioid glioblastoma changed to typical glioblastoma-the methylation status of MGMT promoter and 5-ALA fluorescence (2011)
  • Author(s): Tanaka S, Yano S, et al.
  • Journal Title: Brain Tumor Pathol
  • Peer Reviewed
• [Journal Article] A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. (2011)
  • Author(s): Tomimoto H, Yano S, et al.
  • Journal Title: Oncology Letter Volume: (In press)
  • Peer Reviewed
• [Journal Article] The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. (2011)
  • Author(s): Yasumoto K, Yano S, et al.
  • Journal Title: Clin Cancer Res Volume: (In press)
  • Peer Reviewed
• [Journal Article] Hepatocyte growth factor reduces susceptibility to irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer (2010)
  • Author(s): Yamada T, Matsumoto K, Wang W, Li Q, NishiokaY, Sekido Y, Sone S, Yano S.
  • Journal Title: Clin Cancer Res Volume: 16 Issue: 1 Pages: 174-83
  • DOI: 10.1158/1078-0432.ccr-09-1204
  • NAID: 120001939468
  • Peer Reviewed
• [Journal Article] Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice (2010)
  • Author(s): Sakaguchi S, Goto H, Hanibuchi M, Otsuka S, Ogino H, Kakiuchi S, Uehara H, Yano S, Nishioka Y, Sone S
  • Journal Title: Clin Exp Metastasis Volume: 27 Issue: 5 Pages: 351-9
  • DOI: 10.1007/s10585-010-9333-0
  • Peer Reviewed
• [Journal Article] Hepatocvte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. (2010)
  • Author(s): Yamada T, Yano S, et al.
  • Journal Title: Clin Cancer Res Volume: 16 Pages: 174-183
  • Peer Reviewed
• [Journal Article] Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice. (2010)
  • Author(s): Sakaguchi S, Yano S, et al.
  • Journal Title: Clin Exp Metastasis Volume: 27 Pages: 351-359
  • Peer Reviewed
• [Journal Article] Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage : a rare adverse effect of sunitinib. (2010)
  • Author(s): Yamada T, Yano S, et al.
  • Journal Title: Int J Clin Oncol Volume: 15 Pages: 638-641
  • NAID: 10027665563
  • Peer Reviewed
• [Journal Article] The role of percutaneous needle biopsy in differentiation of renal tumors. (2010)
  • Author(s): Izumi K, Yano S, et al.
  • Journal Title: Jpn J Clin Oncol Volume: 40 Pages: 1081-1086
  • Peer Reviewed
• [Journal Article] Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan. (2010)
  • Author(s): Kanematsu T, Yano S, et al.
  • Journal Title: J Med Invest Volume: 57 Pages: 326-333
  • NAID: 130004465225
  • Peer Reviewed
• [Journal Article] Reaction of plasma hepatocyte growth factor level in lung cancer patients treated with EGFR-TKIs. (2010)
  • Author(s): Tanaka H, Yano S, et al.
  • Journal Title: Int J Cancer Volume: (In press)
  • Peer Reviewed
• [Journal Article] Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts. (2010)
  • Author(s): Shiirevnyamba A, Yano S, et al.
  • Journal Title: Br J Cancer Volume: 104 Pages: 505-513
  • Peer Reviewed
• [Journal Article] Hepatocyte growth factor reduces susceptibility to irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. (2010)
  • Author(s): Yamada T, et al.
  • Journal Title: Clin Cancer Res 16 Pages: 174-183
  • NAID: 120001939468
  • Peer Reviewed
• [Journal Article] Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors (2009)
  • Author(s): Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S
  • Journal Title: Clin Cancer Res Volume: 15 Issue: 21 Pages: 6630-8
  • DOI: 10.1158/1078-0432.ccr-09-1001
  • Peer Reviewed
• [Journal Article] E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangio-genic cytokine production profiles (2009)
  • Author(s): Ikuta K, Yano S, Trung TV, Hanibuchi M, Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, Uehara H, Sekido Y, Uenaka T, Nishioka Y, Sone S
  • Journal Title: Clin Cancer Res Volume: 15 Issue: 23 Pages: 7229-37
  • DOI: 10.1158/1078-0432.ccr-09-1980
  • Peer Reviewed
• [Journal Article] Intensification therapy with anti-para-thyroid hormonerelated protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in SCID mice (2009)
  • Author(s): Yamada T, Muguruma H, Yano S, Ikuta K, Ogino H, Kakiuchi S, Hanibuchi M, Uehara H, Nishioka Y, Sone S.
  • Journal Title: Mol Cancer Ther Volume: 8 Pages: 119-26
  • URL: http://www.ncbi.nlm.nih.gov/pubmed/19139120
  • Peer Reviewed
• [Journal Article] Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. (2009)
  • Author(s): Wang W, et al.
  • Journal Title: Clin Cancer Res 15 Pages: 6630-6638
  • Peer Reviewed
• [Journal Article] Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. (2009)
  • Author(s): Yamada T, et al.
  • Journal Title: Int J Clin Oncol 14 Pages: 468-472
  • NAID: 10027201066
  • Peer Reviewed
• [Journal Article] Cancer of unknown primary site in which tumor marker-oriented chemo therapy was effective and pancreatic cancer was finally confirmed at autopsy. (2009)
  • Author(s): Ohtsubo K, et al.
  • Journal Title: Intern Med 48 Pages: 1651-1656
  • Peer Reviewed
• [Journal Article] E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. (2009)
  • Author(s): Ikuta K, et al.
  • Journal Title: Clin Cancer Res 15 Pages: 7229-7237
  • Peer Reviewed
• [Journal Article] Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in SCID mice. (2009)
  • Author(s): Yamada T, et al.
  • Journal Title: Mol Cancer Ther 8 Pages: 119-126
  • NAID: 120001088425
  • Peer Reviewed
• [Journal Article] HM1.24(CD317)is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. (2009)
  • Author(s): Wang W, et al.
  • Journal Title: Lung Cancer 63 Pages: 23-31
  • Peer Reviewed
• [Presentation] Receptor ligand-triggered resistance to molecular targeted drugs in lung cancer (2011)
  • Author(s): 矢野聖二
  • Organizer: 第52回日本肺癌学会総会
  • Place of Presentation: 大阪国際会議場(大阪府)
  • Year and Date: 2011-11-03
• [Presentation] がん転移のメカニズム (2011)
  • Author(s): 矢野聖二
  • Organizer: 第49回日本癌治療学会学術集会
  • Place of Presentation: 名古屋国際会議場(愛知県)
  • Year and Date: 2011-10-27
• [Presentation] EGFR ligands induce resistance to ALK inhibitors in EML4-ALK lung cancer cells (2011)
  • Author(s): 矢野聖二
  • Organizer: 第70回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場(愛知県)
  • Year and Date: 2011-10-03
• [Presentation] HGF-triggered EGFR-TKI resistance in EGFR mutant lung cancer (2011)
  • Author(s): 矢野聖二
  • Organizer: 第9回日本臨床腫瘍学会学術集会
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2011-07-21
• [Presentation] Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. 2011 American Society of Clinical Oncology(ASCO) (2011)
  • Author(s): Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K
  • Organizer: Annual Meeting
  • Place of Presentation: McCormick Place(USA.)
  • Year and Date: 2011-06-04
• [Presentation] HGFによるEGFR-TKI耐性の分子機構解明とその克服に向けた研究(篠井・河合賞受賞講演) (2010)
  • Author(s): 矢野聖二
  • Organizer: 第51回日本肺癌学会
  • Place of Presentation: 広島国際会議場(広島県) 招待講演
  • Year and Date: 2010-11-04
• [Presentation] マルチキナーゼ阻害薬を用いた胸膜中皮腫の薬物治療 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第51回日本肺癌学会
  • Place of Presentation: 広島国際会議場(広島県)
  • Year and Date: 2010-11-04
• [Presentation] HGFによる肺癌のEGFR-TKI耐性の分子機構解明とその克服に向けた研究 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第51回日本肺癌学会総会
  • Place of Presentation: 広島国際会議場(広島県)
  • Year and Date: 2010-11-03
• [Presentation] EGFR遺伝子変異陽性肺がんにおけるEGFR-TKI耐性の克服 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第48回日本癌治療学会
  • Place of Presentation: 国立京都国際会館(京都府)
  • Year and Date: 2010-10-28
• [Presentation] EGFR肺がんのチロシンキナーゼ阻害薬耐性と治療戦略 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第69回日本癌学会
  • Place of Presentation: 大阪国際会議場(大阪府)
  • Year and Date: 2010-09-23
• [Presentation] EGFR肺がんのチロシンキナーゼ阻害薬耐性と治療戦略 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第69回日本癌学会学術総会
  • Place of Presentation: 大阪国際会議場(大阪府)
  • Year and Date: 2010-09-22
• [Presentation] 肺がんと骨転移 (2010)
  • Author(s): 矢野聖二
  • Organizer: 第28回日本骨代謝学会
  • Place of Presentation: 京王プラザホテル(東京都)
  • Year and Date: 2010-07-22
• [Presentation] 肺がんのEGFR-TKI耐性の分子機構と克服に向けた試み (2010)
  • Author(s): 矢野聖二
  • Organizer: 第14回日本がん分子標的治療学会
  • Place of Presentation: タワーホール船堀(東京都)
  • Year and Date: 2010-07-08
• [Presentation] Therapeutic effect of HGF inhibitors against HGF-induced EGFR-TKI resistance in lung cancer harboring EGFR mutations. (2010)
  • Author(s): 矢野聖二
  • Organizer: 第101回AACR
  • Place of Presentation: Walter E.Washington Convention Center(Washington DC)
  • Year and Date: 2010-04-18
• [Presentation] HGF-MET経路によるEGFR-TKI耐性誘導の分子機構とその克服に向けた戦略 (2009)
  • Author(s): 矢野聖二
  • Organizer: 第50回日本肺癌学会総会
  • Place of Presentation: 京王プラザホテル(東京都)
  • Year and Date: 2009-11-21
• [Presentation] HGF induces resistance to EGFR tyrosine kinase inhibitors in lung cancer with EGFR activating mutations (2009)
  • Author(s): Yano S
  • Organizer: The 14th Congress of the Asian Pacific Society of Respirology
  • Place of Presentation: Convention & Exhibition(Korea)
  • Year and Date: 2009-11-14
• [Presentation] HGF induces resistance to EGFR tyrosine kinase inhibitors in lung cancer with EGFR activating mutations.(招待講演) (2009)
  • Author(s): 矢野聖二
  • Organizer: The 14th Congress of the Asian Pacific Society of Respirology
  • Place of Presentation: Convention and Exibition Center, (Seoul Korea)
  • Year and Date: 2009-11-14
• [Presentation] 肝細胞増殖因子(HGF)はEGFR遺伝子変異T790Mを有する肺腺癌のirreversible EGFR阻害剤の耐性を誘導する (2009)
  • Author(s): 山田忠明
  • Organizer: 第50回日本肺癌学会総会
  • Place of Presentation: 京王プラザホテル(東京都)
  • Year and Date: 2009-11-12
• [Presentation] Stromal Fibroblasts induce resistance of lung cancer to EGFR tyrosine kinase inhibitors. (2009)
  • Author(s): 王偉
  • Organizer: 2009 Asia-Paciffic Conference of Tumor Biology and Medicine
  • Place of Presentation: Hotel JianGuo, (Xian China)
  • Year and Date: 2009-10-24
• [Presentation] Hepatocyte growth factor as an inducer of EGFR-TKI resistance in lung cancer harboring EGFR activating mutations (2009)
  • Author(s): 矢野聖二
  • Organizer: 第68回日本癌学会学術総会
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2009-10-01
• [Presentation] Hepatocyte growth factor as an inducer of EGFR-TKI resistance in lung cancer harboring EGFR activating mutations.(招待講演) (2009)
  • Author(s): 矢野聖二
  • Organizer: 第68回日本癌学会学術総会
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2009-10-01
• [Presentation] EGFR変異とEGFR-TKI:耐性克服の治療戦略. (2009)
  • Author(s): 山田忠明
  • Organizer: 第68回日本癌学会学術総会
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2009-10-01
• [Presentation] Stromal fibroblasts induce resistance of lung cancer to EGFR tyrosine kinase inhibitors. (2009)
  • Author(s): 王偉
  • Organizer: 第18回日本がん転移学会学術集会
  • Place of Presentation: 旭川グランドホテル(旭川市)
  • Year and Date: 2009-07-23
• [Presentation] 肝細胞増殖因子(HGF)はEGFR遺伝子変異T790Mを有する肺線癌のirreversible EGFR阻害剤の耐性を誘導する. (2009)
  • Author(s): 山田忠明
  • Organizer: 第13回日本がん分子標的治療学会学術集会
  • Place of Presentation: ホテルクレメント徳島(徳島市)
  • Year and Date: 2009-06-24
• [Presentation] 肺がんの分子標的薬耐性と微小環境.(招待講演) (2009)
  • Author(s): 矢野聖二
  • Organizer: 第13回日本がん分子標的治療学会学術集会
  • Place of Presentation: ホテルクレメント徳島(徳島市)
  • Year and Date: 2009-06-24
• [Presentation] 宿主由来HGFによる変異型EGFR陽性肺癌のゲフィチニブ耐性機構解析とその克服. (2009)
  • Author(s): 王偉
  • Organizer: 第13回日本がん分子標的治療学会学術集会
  • Place of Presentation: ホテルクレメント徳島(徳島市)
  • Year and Date: 2009-06-24
• [Presentation] EGFR活性型変異を有する肺腺癌における肝細胞増殖因子(HGF)によるゲフィチニブ耐性. (2009)
  • Author(s): 山田忠明
  • Organizer: 第49回日本呼吸器学会学術講演会
  • Place of Presentation: 東京国際フォーラム(東京都)
  • Year and Date: 2009-06-12
• [Remarks]
  • URL: http://syuyounaika.w3.kanazawa-u.ac.jp/
• [Remarks]
  • URL: http://syuyounaika.w3.kanazawa-u.ac.jp/
• [Remarks]
  • URL: http://syuyounaika.w3.kanazawa-u.ac.jp/
• [Remarks]
  • URL: http://www.kanazawa-u.ac.jp/university/administration/prstrategy/eacanthus/1001/05.html
• [Patent(Industrial Property Rights)] 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物 (2009)
  • Inventor(s): 矢野聖二、松本邦夫
  • Industrial Property Rights Holder: 矢野聖二、松本邦夫
  • Filing Date: 2009-10-09
  • Overseas